相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
U. Brunnberg et al.
ANNALS OF ONCOLOGY (2012)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Roland B. Walter et al.
BLOOD (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
Hugo F. Fernandez et al.
BLOOD (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Japan: Universal Health Care at 50 Years 6 Future of Japan's system of good health at low cost with equity: beyond universal coverage
Kenji Shibuya et al.
LANCET (2011)
Cytarabine Dose for Acute Myeloid Leukemia
Bob Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gemtuzumab ozogamicin: is there room for salvage?
W. Thomas Clarke et al.
BLOOD (2010)
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
Bob Lowenberg et al.
BLOOD (2010)
Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe
W. P. C. Boon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
FDA Increases Focus on Postmarketing Studies
Merrill Goozner
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Cancer Clinical Trials - A Chronic but Curable Crisis
Robert C. Young
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study
Yukio Kobayashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?
Elizabeth A. Richey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid Leukemia
Patrice Chevallier et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia
Massimo Breccia et al.
HAEMATOLOGICA (2007)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia:: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori et al.
LEUKEMIA (2005)
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
F Lo-Coco et al.
BLOOD (2004)
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
WJ Kell et al.
BLOOD (2003)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
